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Abstract
Background: Loss to follow-up (LTF) challenges the reporting of antiretroviral treatment (ART) programmes, since it
encompasses patients alive but lost to programme and deaths misclassified as LTF. We describe LTF before and after
correction for mortality in a primary care ART programme with linkages to the national vital registration system.
Methods and Findings: We included 6411 patients enrolled on ART between March 2001 and June 2007. Patients LTF with
available civil identification numbers were matched with the national vital registration system to ascertain vital status.
Corrected mortality and true LTF were determined by weighting these patients to represent all patients LTF. We used
Kaplan-Meier estimates and Cox regression to describe LTF, mortality among those LTF, and true LTF. Of 627 patients LTF,
85 (28.8%) had died within 3 months after their last clinic visits. Respective estimates of LTF before and after correction for
mortality were 6.9% (95% confidence interval [CI] 6.2–7.6) and 4.3% (95% CI 3.5–5.3) at one year on ART, and 23.9% (95% CI
21.0–27.2) and 19.7% (95% CI 16.1–23.7) at 5 years. After correction for mortality, the hazard of LTF was reversed from
decreasing to increasing with time on ART. Younger age, higher baseline CD4 count, pregnancy and increasing calendar
year were associated with higher true LTF. Mortality of patients LTF at 1, 12 and 24 months after their last visits was
respectively 23.1%, 30.9% and 43.8%; 78.0% of deaths occurred during the first 3 months after last visit and 45.0% in
patients on ART for 0 to 3 months.
Conclusions: Mortality of patients LTF was high and occurred early after last clinic visit, especially in patients recently started
on ART. Correction for these misclassified deaths revealed that the risk of true LTF increased over time. Research targeting
groups at higher risk of LTF (youth, pregnant women and patients with higher CD4 counts) is needed.
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Introduction
Loss to follow-up (LTF) is recognised as one of the key
challenges to evaluating the effectiveness of antiretroviral care in
resource-limited settings. Reported rates of LTF vary consider-
ably; one review of antiretroviral treatment programmes in Africa
reported cumulative proportions of lost to care at two years
ranging from 15% to 54% [1]. However, the vital status of those
patients LTF is often unknown, and may include negative
outcomes (such as mortality) and non-negative outcomes (such as
transfers).
Several studies have traced patients lost to care to ascertain their
true status. A recent systematic review of studies reporting
outcomes on patients lost to care, who had been traced to
ascertain their vital status, found that 20% to 60% had died and
37% could not be traced [2]. However, active tracing of all
patients lost to care to ascertain vital status as part of routine
monitoring and evaluation is generally not practical, and
programmes commonly report outcome data simply as those
remaining in care, thus aggregating death and loss to follow up as
programme failures [3,4].
However, beyond samples of patients who are traced for
research purposes, the actual outcomes of a substantial proportion
of patients remain unreported and unknown. High rates of LTF
can result in programme reporting bias, due to inaccurate
estimates of survival, and in biased estimates of risk factors for
death and LTF, since patients lost to follow-up may be at high risk
of death [5]. This is a concern both for individual clinical care and
for programme evaluation, as unstructured interruption of
treatment can lead to the development of drug resistance, [6]
and there is uncertainty as to whether resources should be invested
in defaulter tracing. Correctly detecting and minimising LTF is
therefore a concern for health providers, programme planners and
donors.
South Africa is the only country in sub-Saharan Africa with a
well-functioning vital registration system, with more than 80% of
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deaths recorded in recent years [7], and this provides a unique
opportunity to disentangle misclassified deaths and true loss to
care. We report on mortality and LTF in patients in a primary
care antiretroviral treatment programme in Khayelitsha, an area
of Cape Town, before and after correction for vital status.
Methods
Study setting
The study included all treatment-naive adults initiated on ART
at three public sector primary care clinics in Khayelitsha between
March 2001 and June 2007 and followed up until January 2008.
By the end of 2007, the service had cumulatively enrolled over
7000 adults onto ART. Antenatal HIV prevalence in 2007 was
32.7%. Patients with available civil identification numbers who
were lost to follow-up were matched with the national death
registry to ascertain their vital status.
Eligibility criteria for ART initiation in adults were CD4 cell
count below 200 cells/mL and/or WHO stage IV with the
exception of extrapulmonary tuberculosis. The standard first-line
ART regimen was zidovudine (ZDV) and lamivudine (3TC)
together with nevirapine (NVP) or efavirenz (EFV), with stavudine
(d4T) replacing ZDV in late 2003, consistent with the South
African national guidelines. A second-line regimen (ZDV,
didanosine and lopinavir/ritonavir) is started after virologic failure
is confirmed (two consecutive viral load results above 5000 copies/
mL, in spite of enhanced adherence promotion after the first
elevated result). The Khayelitsha ART programme has been
described in detail elsewhere [8–10].
Study design and key variables
In this prospective cohort study, patient outcomes were death,
LTF or transfer to another facility. Patients were considered as
LTF if their last clinic visit occurred at least 6 months before the
end of the observation period (31 December 2007) and they were
not known to have died or been transferred out. Definitions of loss
to follow up vary considerably in the literature, from one day to
more than one year [10]. Six months as a definition of LTF is
increasingly used for analyses of African HIV treatment cohorts.
This corresponds to at least two missed appointments for patients
who are on a quarterly appointment schedule, which is usually the
longest period between appointments in this setting. This duration
has further been shown to perform best in terms of sensitivity and
specificity from a multi-cohort analysis [11].
True LTF was defined for those patients with civil identification
numbers as being lost to follow-up and not appearing in the national
death registry during the first three months after LTF. Time in care
was calculated from initiation on ART to the last recorded visit
before 30 June 2007. Patients were followed in the analysis until
mid-2007, and data until the end of 2007 were included to
determine if patients met the LTF definition. Right censoring
occurred at time of death or known transfer to another facility.
Time to death in patients lost to follow-up was calculated from date
of last visit until death if this occurred before database closure (25
January 2008), with right censoring of all patients who remained
alive at this point. There was no uncensoring in either analysis.
Data sources
The Khayelitsha programme serves as a sentinel monitoring site
for the Western Cape Province. Data are captured routinely by
health providers using structured clinical records, and these data
are transferred to an on-site electronic patient information system
by dedicated data clerks. Rule-based consistency and completeness
checks are used to routinely audit the database.
South Africa’s vital registration system has a high level of
completeness and is rapidly updated. Citizens with identity
documents have their details recorded on the national population
register, and this register is updated immediately when a death is
notified, before the detailed death notification form is processed by
the central statistical office. Linkage to the population register
therefore allows for a rapid assessment of mortality in those
patients who have identity documents. There are strong
administrative incentives for reporting deaths, and the complete-
ness of death registration, especially in urban areas, has improved
dramatically over the past decade. Sensitivity and specificity of the
ascertainment of death through the national population registry
has been assessed for this cohort at 90.5% and 99.9%, respectively
[10]. This is consistent with estimates from local demographers as
well as results from other studies using death registry linkages in
South Africa [11].
Statistical analysis
Descriptive analyses were based on percentages and frequencies
for categorical variables, and medians and interquartile ranges
(IQR) for continuous variables. To correct for unreported mortality
among patients lost to follow-up, the updated vital status among lost
patients for whom civil identification numbers were available was
used to represent outcomes among all those lost to follow-up by
generating a probability weighting (the ratio of all patients lost to
follow-up to those lost for whom civil identification numbers were
available). Lost patients with national death registry-updated vital
status were assigned this weight, and all other lost patients were
dropped from the analysis [3,10]. We used weighted Kaplan-Meier
estimates to describe time to loss to follow up and Cox regression
models based on weighted and unweighted data to explore factors
associated with loss to follow up and true LTF. Age, sex, and CD4
count were included in the multivariate models on a priori grounds.
In addition, variables found to be associated with the outcome in the
univariate analysis (p,0.25) were included in the multivariate model
building process and retained if supported by likelihood ratio testing.
Bootstrap confidence intervals for the weighted Kaplan–Meier
failure estimates were calculated by sampling from the dataset with
replacement 1000 times. Kaplan-Meier analysis and Cox propor-
tional hazards regression were used to describe mortality and factors
associated with death among the sub-sample of patients lost to
follow-up for whom vital status data was available. A Wald test for
linear hypotheses after estimation was used for ordinal variables
(CD4 count, WHO stage, calendar year of initiation on ART, and
drug regimen). All analyses were conducted using Stata statistical
software, version 11.0 (Stata-Corp, College Station, Texas, USA).
Ethics
The analysis of routine cohort data and the linkage to the
national death registry were both approved by the University of
Cape Town Research Ethics Committee. All data were anon-
ymised prior to being made available for analysis.
Results
Cohort description
During the period under analysis, 6411 treatment-naive adult
patients were initiated on ART, totalling 9846 person-years of
observation. Annual enrolment on ART increased from 80 in
2001 to 2090 in 2006. The median age at enrolment on ART was
32 years (interquartile range [IQR] 28–39) and 68% were women
(Table 1). Men were older than women (median age 36 vs. 31,
p,0.001). At initiation of ART, patients truly lost to follow-up
were younger (median age 31 vs. 33 years, p,0.001), had a higher
LTF and Mortality on ART
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CD4 count (median 116 vs. 99 cells/mL, p= 0.012), a lower WHO
stage (34% vs. 37% with stage IV disease, p = 0.077), were more
likely to be pregnant (6.2% vs. 2.0%, p,0.001), and initiated in
later calendar years (p = 0.001) than patients not lost to follow-up;
37% of all patients were on treatment for tuberculosis and 8% had
been exposed to prevention of mother-to-child transmission.
Loss to follow up
At the end of June 2007, 4967 (77.5%) patients were alive and
in care, 512 (8.0%) had died, 305 (4.8%) had been transferred to
another facility, and 627 (9.8%) were lost to follow-up (Figure 1).
Civil identification numbers were available for 295 (47.0%) of all
patients lost to follow-up. Ascertainment of their vital status
through the national death registry revealed that 85 (28.8%) had
died within three months of LTF, 95 had died before 30 June
2007, and 109 before 25 January 2008. The only difference
between patients LTF with and without available identification
numbers was in the median CD4 count (respectively, 101 cells/
mLmL, IQR 48–163 with, and 82, IQR 34–143 without identity
documents, p = 0.007).
Respective cumulative estimates of LTF before and after
correction for mortality were 6.9% (95% CI 6.2–7.6) and 4.3%
(95% CI 3.5–5.3) at one year on ART, 16.4% (95% CI 15.0–17.9)
and 13.4% (95% CI 11.5–15.6) at three years, and 23.9% (95% CI
21.0–27.2) and 19.7% (95% CI 16.1–23.7) at 5 years (Figure 2).
Before correction for mortality, the hazard of LTF decreased with
increasing duration on ART (Figure 3). However, after correction,
the hazard of true LTF was found to increase with time on ART.
The cumulative proportion truly lost to follow-up at three months
on ART increased from 0% in 2001–2004 to 1.7% in 2005, but
then remained stable at 2.1% in 2006 and 2.3% in 2007 (Figure 4);
true LTF at one year increased from 0% in 2001 to 2003, to 1.7%
in 2004, 3.8% in 2005, and 7.6% in 2006.
Risk factors for LTF using routine data (prior to vital status
linkage) were male sex (hazard ratio [HR] 1.32, p = 0.003),
younger age (per 5 years older, HR 0.94, p = 0.027), lower weight
(per 10 kg, HR 0.87, p,0.001) and increasing calendar year of
initiation on ART (p,0.001; Table 2). After correction for
mortality, younger age (HR 0.87, p= 0.017) and increasing
calendar year (p,0.001) remained associated with true LTF, but
Table 1. Patient characteristics at initiation of ART.
All Not LTF* True LTF**
Total enrolled, n 6411 5869 210
Male sex, n (%) 2067 (32) 1864 (32) 67 (32)
Age, years Women, median (IQR) 31 (27–37) 31 (27–37) 30 (25–34)
Men, median (IQR) 36 (31–42) 36 (31–42) 33 (30–38)
Weight, kg Tested, n (%) 6198 (97) 5681 (97) 194 (92)
Median (IQR) 59 (52–67) 59 (52–67) 59 (53–67)
CD4 count, (cells/mL) Tested, n (%) 5963 (93) 5462 (93) 195 (93)
Median (IQR) 99 (44–161) 99 (43–161) 116 (57–173)
Viral load, (copies/ml) Tested, n (%) 3487 (54) 3154 (54) 126 (60)
Log10, Median (IQR) 5.0 (4.6–5.6) 5.0 (4.6–5.6) 5.1 (4.6–5.5)
WHO stage, n (%) I 359 (6) 327 (6) 20 (10)
II 567 (9) 526 (9) 15 (7)
III 3127 (49) 2855 (49) 104 (50)
IV 2358 (37) 2161 (37) 71 (34)
History of PMTCT, n (%) 508 (8) 460 (8) 19 (9)
Pregnant, n (%) 139 (2) 120 (2) 13 (6)
On TB treatment, n (%) 2370 (37) 2159 (37) 75 (36)
Antiretroviral regimen, n (%) AZT/3TC/NVP 470 (7) 429 (7) 22 (11)
AZT/3TC/EFV 603 (9) 553 (9) 17 (8)
D4T/3TC/NVP 2554 (40) 2357 (40) 81 (39)
D4T/3TC/EFV 2748 (43) 2500 (43) 87 (42)
Year of ART initiation, n (%) 2001 82 (1) 76 (1) 1 (0)
2002 205 (3) 195 (3) 4 (2)
2003 389 (6) 354 (6) 11 (5)
2004 1063 (17) 949 (16) 36 (17)
2005 1643 (26) 1482 (25) 76 (36)
2006 2090 (33) 1902 (32) 69 (33)
2007 (Jan–June) 939 (15) 911 (16) 13 (6)
ART, antiretroviral treatment; LTF, Lost to follow-up; IQR, interquartile range; PMTCT, prevention of mother to child transmission; TB, tuberculosis; AZT, zidovudine; 3TC,
lamivudine; NVP, nevirapine; D4T, stavudine; EFV, efavirenz.
* All patients not lost to follow-up, including deaths occurring within 3 months after loss to follow-up;
** Patients lost to follow-up with available civil identification number who were alive 3 months after being lost.
doi:10.1371/journal.pone.0014684.t001
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there was no longer an association with sex or weight. Higher
baseline CD4 count (p = 0.059) and pregnancy (HR 1.85,
p = 0.072) were both associated with true LTF, whereas these
factors were not associated with LTF when mortality was not
taken into account. In univariate analyses, being on TB treatment
at initiation of ART and antiretroviral regimens were both
associated with LTF and true LTF. However, these associations
were no longer present in multivariate analyses, suggesting
confounding (by CD4 count for TB treatment and by calendar
year for antiretroviral regimens).
Mortality of patients lost to follow-up
Of the 295 patients LTF for whom vital status could be
ascertained, 109 (36.9%) had died. Cumulative mortality of
patients LTF at 1, 2, 3, 6, 12, 18 and 24 months after their last
clinic visit was respectively 23.1%, 27.5%, 29.2%, 30.9%,
34.9%, 41.3%, and 43.8%. Thus, 78.0% (85/109) of deaths
occurred within the first 3 months after their last clinic visit
(Figure 5 A).
Mortality of patients lost to follow-up occurred predominantly
in patients who had started ART recently, with 49/109 (45.0%)
deaths in patients who were LTF when on ART for less than 3
months (Figure 5 B). For patients reported as lost during the first 3
months on ART, mortality at 3 months after their last clinic visit
was stable at around 50% from 2005 to 2007.
Mortality of patients reported LTF at one month after their
last clinic visit was, respectively, 48.3%, 25.0%, 11.5%, and
8.5% in patients on ART for 0–3 months, 3–6 months, 6–12
months and more than 12 months when lost (Figure 5 C).
Patients lost to follow-up with a baseline CD4 count below 50
cells/mL were at increased risk of death (Figure 5 D). In
multivariate analysis, baseline risk factors for death among
patients lost to follow-up for whom vital status was available
were lower weight (per additional 10kg, HR 0.75, p = 0.010),
lower CD4 count (p = 0.011), and increasing calendar year of
initiation (p = 0.012) (Table 3).
Discussion
Our study presents data from one of the largest cohorts of
patients lost to follow up in a resource-limited setting where
Figure 1. Summary diagram of patient outcomes.
doi:10.1371/journal.pone.0014684.g001
Figure 2. Cumulative probability of LTF before and after
correction for mortality. Kaplan-Meier estimates of cumulative
probability of loss to follow-up (LTF) before and after correction for
mortality by ascertainment of vital status of patients lost to follow-up
through the national vital registration system. Routine monitoring
overestimated LTF by 4% at 5 years on ART (23.9 vs. 19.7%).
doi:10.1371/journal.pone.0014684.g002
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linkages to national death registry allowed for ascertainment of
vital status. We found that in the first few months on ART half of
patients LTF had in fact died. True LTF, in which the majority
of patients were alive when missing clinical appointments for six
months or more, was nevertheless an important independent
outcome, cumulatively accounting for a fifth of patients by five
years on ART, and increasing in recent years among patients on
ART for more than a year. Importantly, we found that
subsequent to vital registry linkage, novel associations with true
LTF emerged that were not apparent before correcting for
mortality, including pregnancy and less severe immunodeficiency
at ART initiation.
High early mortality among those reported as LTF
High mortality in patients lost to follow-up has been described
by other large ART programs in sub-Saharan Africa [12], often
implying that patients lost to follow-up are at an increased risk
/>of subsequent mortality. This study, however, demonstrates
that in the early months on ART, mortality most likely preceded
the missed appointments in patients who died and met LTF
definitions. These patients more correctly represent misclassified
deaths than patients lost to follow-up. Community-based
retention strategies comprising early defaulter tracing might
have very low efficiency if more than half the patients traced
<!?show=to]had already died. Conversely, increased clinical
attention to and triaging of patients at high risk of death might
decrease early mortality. Our finding that low baseline weight
and CD4 count and recency of ART initiation are associated
with higher mortality is consistent with other studies and points
to the need to enrol patients earlier in their disease progression
[10,13–15].
Increasing true LTF with duration on ART
The finding that, after correction for mortality, the rate for true
LTF increases with duration on ART has implications both for
patient care and cohort monitoring. This finding is consistent with
previous studies that were not able to correct for misclassified
deaths [16] and highlights the need for adapted counselling and
adherence support interventions for patients on long-term ART.
Possible reasons for this include treatment fatigue and improved
Figure 3. Smoothed hazard of loss to follow-up before and after ascertainment of vital status. Smoothed hazard estimates for loss to
follow-up (LTF) before (A) and after (B) correction for mortality. Before ascertainment of vital status the hazard of LTF decreased over time on ART;
after correcting LTF for mortality, the hazard of true LTF increased with time on ART.
doi:10.1371/journal.pone.0014684.g003
Figure 4. Cumulative probability of true LTF by year of
initiation on ART. Weighted Kaplan-Meier estimates of true LTF by
year of initiation on ART. True LTF increased and occurred earlier with
each calendar year, as enrolment on ART increased.
doi:10.1371/journal.pone.0014684.g004
LTF and Mortality on ART
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immunological and clinical status leading to patients no longer
seeing the need for medication.
Increasing true LTF with calendar time
The overall proportion of people lost to follow-up in our cohort
is low compared to that reported in many other studies [1–2,16],
but increased as the programme expanded. The most likely
explanation is that major scale up of enrolment onto ART has
come at a cost, with reduced quality of counselling, less intensive
clinical care, and less support provided to individual patients.
Initially, access to ART care was limited and patients were
required to meet stringent criteria before being eligible for
treatment [17]; these patients who successfully managed to access
treatment in the early years may differ from those accessing care in
more recent years. Decentralisation of care to peripheral sites [18]
and community support have been found to be associated with
reduced LTF and mortality [19], and such models could be
explored as cohorts expand.
Comparing mortality in those lost to follow-up with
other programmes
Overall, the majority of deaths occurred among patients who were
being followed in care (8%) compared with those who were truly lost
to follow-up (3%). This is in contrast to other programmes in Africa,
where most mortality has been reported to occur among patients who
were reported as lost to follow-up [2]. In the absence of verification of
vital status through death registration, our cohort would have
underestimated cumulative mortality at one year by around 3% [10],
with one third of deaths being misclassified as patients lost to follow-
up. This contrasts sharply with a recent study from Botswana that
estimated that 60% of deaths in the first year were among those lost to
follow up [5]. The most likely explanation for this difference is a
Table 2. Cox proportional hazards models of factors associated with loss to follow-up before and after correction for mortality.
Loss to follow-up (prior to linkage) True loss to follow-up (after linkage)
Univariate Multivariate Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Male gender 1.38 1.18–1.62 ,0.001 1.32 1.10–1.58 0.003 0.94 0.70–1.26 0.673 1.10 0.80–1.53 0.553
Age (per five
year increase)
0.98 0.93–1.02 0.320 0.94 0.89–0.99 0.027 0.87 0.79–0.97 0.010 0.87 0.78–0.98 0.017
Weight (per
10 kg increase)
0.86 0.80–0.92 ,0.001 0.87 0.81–0.94 ,0.001 0.98 0.87–1.10 0.712
CD4 count
(cells/mL)
0–49 0.94 0.75–1.18 0.793 1.00 0.74–1.35 0.223 0.49 0.33–0.73 0.002 0.62 0.41–0.93 0.059
50–150 0.93 0.76–1.15 1.04 0.80–1.37 0.70 0.50–0.99 0.80 0.58–1.11
.150 (ref.) 1.00 - 1.00 - 1.00 - 1.00 -
WHO stage I (ref.) 1.00 - 0.821 1.00 - 0.034 1.00 - 0.240
II 0.89 0.57–1.39 0.50 0.25–0.98 0.49 0.23–1.04
III 0.86 0.60–1.22 0.50 0.31–0.82 0.74 0.43–1.28
IV 0.84 0.59–1.21 0.48 0.28–0.80 0.85 0.48–1.51
On TB treatment 1.37 1.17–1.61 ,0.001 1.12 0.83–1.51 0.445
Year of initiation
of ART
2001/2/3 (ref.) 1.00 - ,0.001 1.00 - ,0.001 1.00 - ,0.001 1.00 - ,0.001
2004 3.11 2.05–4.7 3.22 2.09–4.95 5.84 2.33–14.65 6.43 2.25–18.37
2005 6.00 3.92–9.19 5.71 3.66–8.92 10.58 3.85–29.06 10.17 3.24–31.89
2006 11.72 7.56–18.18 12.42 7.84–19.69 22.80 8.25–62.99 25.07 8.03–78.26
2007 12.90 7.60–21.88 14.75 8.35–26.07 23.17 7.28–73.77 28.09 7.92–99.59
Viral load (log10
copies/mL)
1.09 0.96–1.25 0.207 1.09 0.86–1.37 0.486
Exposure to
PMTCT
0.81 0.61–1.08 0.153 0.86 0.54–1.38 0.535
Pregnancy 1.60 1.01–2.53 0.043 3.02 1.76–5.2 ,0.001 1.85 0.95–3.62 0.072
Antiretroviral
regimen
AZT/3TC/NVP 0.89 0.63–1.25 ,0.001 1.03 0.59–1.79 0.012
AZT/3TC/EFV 0.60 0.43–0.82 0.47 0.26–0.83
D4T/3TC/NVP
(ref.)
1.00 - 1.00 -
D4T/3TC/EFV 1.60 1.34–1.91 1.21 0.88–1.67
ART, antiretroviral treatment; WHO, World Health Organization; HR, hazard ratio; CI, confidence interval; PMTCT, prevention of mother to child transmission; TB,
tuberculosis; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; D4T, stavudine; EFV, efavirenz. P-values for CD4 count, WHO stage, year of initiation on ART and
antiretroviral regimen are from Wald test for linear hypothesis after estimation. After correction for mortality, loss to follow-up was not associated with male gender or
weight anymore, while new associations emerged with higher baseline CD4 counts and pregnancy at initiation of ART.
doi:10.1371/journal.pone.0014684.t002
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substantially higher proportion of early reported LTF and corrected
mortality (after tracing) in this cohort (17% and 17% at one year in
the Botswana cohort vs. 7% and 10% in our cohort). Other notable
differences include a smaller sample size (410 vs. 6411) and follow-up
duration (median follow up time 44 weeks vs. 5 years) and a sicker
population accessing ART (median CD4 81 vs. 99 cells/mm3). Our
data are, however, comparable to other data in South Africa [19].
Risk factors for loss to follow up
Cohort monitoring helps in the identification of potential risk
factors for true LTF based on patient characteristics. This allows
programme implementers to focus counselling on various high-risk
groups such as, in this instance, pregnant women and adolescents.
A more thorough understanding of reasons for defaulting requires
tracing of patients. Such studies have identified a number of risk
factors including cost of treatment [20], improved or deteriorated
health [2], stigma [21], fear of drug side-effects [22], loss of hope
in medications [23], substance misuse [23], lack of money for
transport [10,23] and work or family responsibilities [23]. A recent
modelling study reported that implementing a number of
approaches to overcome commonly reported barriers to remaining
in care such as removal of user fees and support with transport
costs would be cost-effective [24]. However, there remains a
paucity of implementation studies to limit defaulting in resource-
limited settings. This is in contrast to adherence interventions, for
which a multitude of randomised trials have been done or are
underway and focus on adherence in patients who remain in care,
often predominantly soon after initiating ART [25].
At the end of 2009 the World Health Organization recom-
mended that ART initiation be started earlier in resource-limited
settings [26]. In line with these new recommendations South
Africa recently changed the eligibility criteria for ART to include
all pregnant women and patients diagnosed with tuberculosis who
are HIV infected and have a CD4 count below 350 cells/mL [27]
compared to only patients with a CD4 count below 200 cells/mL.
Our findings that both pregnant women and patients with higher
CD4 counts are at a greater risk of leaving care point to the need
for adapted adherence support for these groups. A previous study
from the same setting has raised similarly concerns about the
retention in care of pregnant women who are started on ART
[28].
Strengths and limitations
Our study has several strengths and limitations. Representative
sampling of patients lost to care to verify vital status has been
proposed as a way to obtain accurate mortality estimates [4]. We
used death registry linkages to estimate true LTF estimates in
South Africa. Our finding that mortality among those lost to care
increased over time cautions against the use of cross-sectional
tracing studies at a one point in time for correcting cohort
mortality. Tracing studies are, however, able to collect first-hand
accounts of reasons for loss to care besides mortality, which can be
used to inform programme design and appropriate interventions.
Both approaches are subject to potential biases: in the case of
sampling, there may be differences between those who are traced
and those who could not be traced; in the case of vital registration
Figure 5. Cumulative mortality after LTF. These Kaplan-Meier graphs show cumulative mortality over time after the last recorded visit for
patients originally classified as LTF in whom vital status could be ascertained through the national vital registration system: A - among all LTF; B -
among LTF on ART for less than 3 months; C stratified by duration on ART at time of LTF; D stratified by CD4 cell count at initiation on ART. Patients
recently started on ART and with lower CD4 counts had higher mortality after LTF. LTF, loss to follow-up.
doi:10.1371/journal.pone.0014684.g005
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linkages, there may be differences between those with and without
civil identification numbers. The slightly lower median CD4 count
in patients without civil identification numbers suggests that
mortality among LTF might be underestimated in this analysis.
Recent studies have highlighted the fact that a proportion of
patients who are LTF in fact interrupt treatment for transient
periods, returning at a later date [29]. We are unable to report on
rates of interruption in our cohort. Our approach however avoids
the possibility of double counting patients who were LTF more
than once by excluding from our definition of LTF patients
initially lost to follow up who later returned to care.
Another limitation, from a programme perspective, is that this
study has focused only on LTF among patients who had initiated
ART. High mortality and LTF has also been documented among
patients waiting to be placed on ART [30], and similar studies are
needed to explore risk factors for such pre-ART defaulting from
care to help develop strategies to retain people in care prior to
ART initiation [31].
Finally, it should be noted that this study was done in a peri-
urban township setting with a high patient load, a high incidence
of tuberculosis, and a high prevalence of HIV. The described
cohort is representative of many scale-up treatment settings in
South Africa and beyond. The increase with time in LTF is shared
by a number of cohorts in South Africa [14], and the key findings
from this analysis are of potential relevance to these and other
cohorts in the region. Service and patient factors relating to loss to
follow-up and the completeness of mortality registration are
however affected by context, highlighting the importance of
exploring the extent of and associations with true loss to follow-up
in different settings.
Relevance for policy and practice
As ART programmes worldwide grow larger, often with limited
resources, increasing numbers of patients are lost to follow-up.
Knowing the vital status of these patients is essential to design
interventions to prevent loss to follow-up or to return these
patients to care. First, this study shows that a large proportion of
patients LTF during the first three months after starting ART died
shortly after their last visit. There is thus a need to improve
detection and care of patients at high risk of death during the first
months on ART, e.g. by increasing clinical monitoring and the
frequency of clinical visits for patients with low CD4 counts. In
addition, these findings support earlier initiation of ART to
prevent early mortality. Secondly, the finding that true LTF
increased with time on ART confirms the need to develop
adherence support strategies adapted to long-term ART. Cur-
rently, most ART programmes in resource-limited settings focus
almost exclusively on early adherence support. And thirdly, this
study confirms that younger age, pregnancy, and being started on
ART with a higher CD4 count are risk factors for LTF.
Table 3. Cox proportional hazards models of factors associated with mortality after reported loss to follow-up.
Univariate Multivariate
HR 95% CI p HR 95% CI p-value
Male gender 1.69 1.16–2.47 0.007 1.14 0.74–1.76 0.559
Age (5 years older) 1.16 1.07–1.27 0.001 1.07 0.96–1.19 0.250
Weight (10 kg more) 0.68 0.57–0.82 ,0.001 0.75 0.61–0.93 0.010
CD4 count (cells/mL) 0–49 3.40 1.89–6.12 ,0.001 2.68 1.40–5.14 0.011
50–150 2.19 1.23–3.88 1.81 0.97–3.38
.150 (ref.) 1.00 - 1.00 -
WHO stage I (ref.) 1.00 - 0.113 1.00 - 0.818
II 2.94 0.76–11.37 1.75 0.33–9.27
III 3.18 0.99–10.18 1.83 0.42–8.0
IV 3.97 1.23–12.75 2.03 0.45–9.11
On TB treatment 1.61 1.11–2.35 0.013
Year of initiation of ART 2001–2003 (ref.) 1.00 - ,0.001 1.00 - 0.012
2004 0.77 0.23–2.65 0.73 0.21–2.55
2005 1.67 0.59–4.69 1.92 0.67–5.51
2006 2.36 0.85–6.58 2.13 0.74–6.13
2007 4.59 1.54–13.71 4.22 1.25–14.21
Viral load (log10 copies/mL) 1.18 0.81–1.74 0.391
Exposure to PMTCT 0.30 0.09–0.94 0.038
Pregnancy 0.15 0.02–1.08 0.060
Antiretroviral regimen AZT/3TC/NVP 0.23 0.05–0.94 0.002
AZT/3TC/EFV 0.71 0.28–1.82
D4T/3TC/NVP (ref.) 1.00 -
D4T/3TC/EFV 1.70 1.13–2.57
ART, antiretroviral treatment; WHO, World Health Organization; HR, hazard ratio; CI, confidence interval; PMTCT, prevention of mother to child transmission; TB,
tuberculosis; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; D4T, stavudine; EFV, efavirenz. P-values for CD4 count, WHO stage, year of initiation on ART and
antiretroviral regimen are from Wald test for linear hypothesis after estimation.
doi:10.1371/journal.pone.0014684.t003
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Programmes must be adapted to provide targeted support to youth
and pregnant women, while more research is needed into
adherence support that addresses the needs of patients with higher
CD4 counts.
Conclusions
Our study has demonstrated how the failure to verify deaths in
the early months on ART impacts on the reported LTF on ART,
and how, after correction for this misclassification, true loss to
follow-up is increasing with both calendar time and duration on
ART. The risk factors for true loss to follow-up identified by our
study—higher CD4 and pregnancy— are likely to become more
prevalent as countries adopted the latest WHO guidelines. This
highlights the need for efficient real-time cohort monitoring and
patient tracing as well as the development and implementation of
interventions to reduce loss to follow-up among those at greatest
risk. Finally, more must be done to prevent early mortality. The
majority of ART programmes are unable to undertake such
extensive monitoring as presented here; such deaths are wrongly
misclassified as LTF, and therefore essentially invisible. Intensified
clinical monitoring is needed for patients at high risk of death
during the first months on ART.
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